Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with ...

Idorsia, which is no stranger to needing to find cash quickly, also said it has raised 150 million Swiss francs ($167 million ...

AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...

Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

The FDA is further elevating a pacemaker recall from Boston Scientific that it first broadcast in December over certain ...

For the last six weeks, the shadow of potential layoffs has hung over Repare Therapeutics’ employees. Monday, staff learned ...